Cuicui Zhang1,2,3,4,5, Yongsheng Jia1,2,3,4,6, Yanan Jia1,2,3,4,5, Xiaoling Zhang1,2,3,4,5, Kai Li7,8,9,10,11. 1. Tianjin Medical University Cancer Institute and Hospital, Tianjin, 300060, People's Republic of China. 2. National Clinical Research Center for Cancer, Tianjin, 300060, People's Republic of China. 3. Key Laboratory of Cancer Prevention and Therapy, Tianjin, 300060, People's Republic of China. 4. Tianin's Clinical Research Center for Cancer, Tianjin, 300060, People's Republic of China. 5. Department of Thoracic Oncology, Tianjin Medical University Cancer Institute and Hospital, Huanhuxi Rd, Tiyuanbei, Hexi District, Tianjin, People's Republic of China. 6. Thyroid and Neck Department, Tianjin Medical University Cancer Institute and Hospital, Tianjin, 300060, People's Republic of China. 7. Tianjin Medical University Cancer Institute and Hospital, Tianjin, 300060, People's Republic of China. likai_fnk@163.com. 8. National Clinical Research Center for Cancer, Tianjin, 300060, People's Republic of China. likai_fnk@163.com. 9. Key Laboratory of Cancer Prevention and Therapy, Tianjin, 300060, People's Republic of China. likai_fnk@163.com. 10. Tianin's Clinical Research Center for Cancer, Tianjin, 300060, People's Republic of China. likai_fnk@163.com. 11. Department of Thoracic Oncology, Tianjin Medical University Cancer Institute and Hospital, Huanhuxi Rd, Tiyuanbei, Hexi District, Tianjin, People's Republic of China. likai_fnk@163.com.
Abstract
BACKGROUND: To investigate the predictive value of plasma D-dimer levels for short-term therapeutic effect and progression-free survival (PFS) in patients with small-cell lung cancer (SCLC); and to analyze the correlation between baseline plasma D-dimer levels and other clinicopathological features. The aim of the study was to investigate whether the levels of plasma D-dimer could serve as a predictive and prognostic factor in patients with SCLC. METHODS: A retrospective review of the clinicopathological data of 160 patients with pathologically confirmed SCLC, who were treated at the Department of Thoracic Oncology of Tianjin Medical University Tumor Institute and Hospital between June 2011 and June 2016, was performed. At the same time, we collected 100 patients with benign pulmonary diseases as a control group. The correlations between baseline plasma D-dimer levels and other clinical features, therapeutic effect and PFS were analyzed statistically. RESULTS: The level of plasma D-dimer in patients with SCLC was significantly higher than that of patients with benign pulmonary diseases (P = 0.001). The PFS of patients with elevated D-dimer levels before therapy were significantly shorter than that of patients with normal D-dimer levels (6.0 versus 7.5 months, P = 0.013). The patients whose plasma D-dimer level always (before and after treatment) in the normal range have the best prognosis, and continuously elevated D-dimer carried out a poor prognosis (8.0 versus 5.0 months). According to multivariate analysis, elevated D-dimer level was confirmed to be an independent prognostic factor for worse survival (P = 0.029). The level of D-dimer was associated with tumor stage, the level of neuron-specific enolase, the presence of distant metastasis, hyponatremia, and the Karnofsky performance status score; and levels decreased when therapy was effective, but increased when the disease progressed. CONCLUSIONS: High levels of baseline plasma D-dimer may indicate advanced disease stage and poor prognosis. Therefore, plasma D-dimer levels could serve as a predictive and prognostic factor in patients with SCLC.
BACKGROUND: To investigate the predictive value of plasma D-dimer levels for short-term therapeutic effect and progression-free survival (PFS) in patients with small-cell lung cancer (SCLC); and to analyze the correlation between baseline plasma D-dimer levels and other clinicopathological features. The aim of the study was to investigate whether the levels of plasma D-dimer could serve as a predictive and prognostic factor in patients with SCLC. METHODS: A retrospective review of the clinicopathological data of 160 patients with pathologically confirmed SCLC, who were treated at the Department of Thoracic Oncology of Tianjin Medical University Tumor Institute and Hospital between June 2011 and June 2016, was performed. At the same time, we collected 100 patients with benign pulmonary diseases as a control group. The correlations between baseline plasma D-dimer levels and other clinical features, therapeutic effect and PFS were analyzed statistically. RESULTS: The level of plasma D-dimer in patients with SCLC was significantly higher than that of patients with benign pulmonary diseases (P = 0.001). The PFS of patients with elevated D-dimer levels before therapy were significantly shorter than that of patients with normal D-dimer levels (6.0 versus 7.5 months, P = 0.013). The patients whose plasma D-dimer level always (before and after treatment) in the normal range have the best prognosis, and continuously elevated D-dimer carried out a poor prognosis (8.0 versus 5.0 months). According to multivariate analysis, elevated D-dimer level was confirmed to be an independent prognostic factor for worse survival (P = 0.029). The level of D-dimer was associated with tumor stage, the level of neuron-specific enolase, the presence of distant metastasis, hyponatremia, and the Karnofsky performance status score; and levels decreased when therapy was effective, but increased when the disease progressed. CONCLUSIONS: High levels of baseline plasma D-dimer may indicate advanced disease stage and poor prognosis. Therefore, plasma D-dimer levels could serve as a predictive and prognostic factor in patients with SCLC.
Authors: Ana M Gil-Bernabé; Spela Ferjancic; Monika Tlalka; Lei Zhao; Philip D Allen; Jae Hong Im; Karla Watson; Sally A Hill; Ali Amirkhosravi; John L Francis; Jeffrey W Pollard; Wolfram Ruf; Ruth J Muschel Journal: Blood Date: 2012-02-10 Impact factor: 22.113
Authors: Frank Gieseler; Inke Lühr; Thomas Kunze; Christoph Mundhenke; Nicolai Maass; Tobias Erhart; Momme Denker; Dennis Beckmann; Markus Tiemann; Christoph Schulte; Peter Dohrmann; Françoise Cavaillé; François Godeau; Christian Gespach Journal: Thromb Haemost Date: 2007-06 Impact factor: 5.249
Authors: Lili Ge; Guangquan Liu; Kai Hu; Ke Huang; Mi Zhang; Juan Zhou; Fang Teng; Jian Cao; Chencheng Dai; Xuemei Jia Journal: Technol Cancer Res Treat Date: 2020 Jan-Dec